Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2015

View Archived Issues

AmorChem licenses mucoadhesive nanoparticle technology from University of Waterloo

JDRF supports Janssen's disease interception approach to prevent onset of type 1 diabetes

Cidara Therapeutics completes financing round to support pipeline

Cipla's U.K. subsidiary enters into a joint venture with Cooper Pharma and PHI

DARPA awards contract to SRI Biosciences to discover synthetic polymer drugs

Novigenix acquires colon cancer blood test Colox

AC Immune receives MJFF grant to develop PET tracer for Parkinson's disease diagnosis

Clinigen opens global access program for ceftazidime/avibactam

Epitarget and IC Contrast complete merger

Promising data revealed on a novel Ebola vaccine candidate

Novavax begins phase I Ebola vaccine trial

Horizon Pharma submits IND application for Actimmune for Friedreich's ataxia

Shanghai Institute Materia Medica discloses new alpha1A-adrenoreceptor antagonists

Vernalis and Servier patent novel Bcl-2 inhibitors

Novartis reports new apelin receptor agonists

New FXIa inhibitors designed by Bayer

Capsule depolymerase EnvD shows efficacy in an inhalation model of anthrax

Scientists at Instituto Italiano di Tecnologia disclose FAAH inhibitors

FDA approves lenvatinib for thyroid cancer

First in vivo results presented of novel ricin and Shigatoxin trafficking inhibitors

Lassa fever recombinant vaccine shows enhanced immunogenicity in mice

FDA accepts NDA for Pfizer's abuse-deterrent formulation of oxycodone

FDA approves sNDA for rufinamide in Lennox-Gastaut syndrome in children aged 1-4 years

Novartis's LCZ-696 to receive FDA priority review for heart failure

N9-GP shows efficacy in pediatric hemophilia B patients

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...